MBOT
Price
$3.96
Change
-$0.21 (-5.05%)
Updated
Aug 26, 04:31 PM (EDT)
Capitalization
189.47M
73 days until earnings call
SYBX
Price
$1.46
Change
-$0.02 (-1.35%)
Updated
Aug 26, 04:05 PM (EDT)
Capitalization
17.31M
Interact to see
Advertisement

MBOT vs SYBX

Header iconMBOT vs SYBX Comparison
Open Charts MBOT vs SYBXBanner chart's image
Microbot Medical
Price$3.96
Change-$0.21 (-5.05%)
Volume$2.1K
Capitalization189.47M
Synlogic
Price$1.46
Change-$0.02 (-1.35%)
Volume$300
Capitalization17.31M
MBOT vs SYBX Comparison Chart in %
Loading...
MBOT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 6.84B. The market cap for tickers in the group ranges from 658 to 185.31B. TMO holds the highest valuation in this group at 185.31B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 3%. For the same Theme, the average monthly price growth was 19%, and the average quarterly price growth was 40%. XFOR experienced the highest price growth at 59%, while VKTX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -58%. For the same stocks of the Theme, the average monthly volume growth was 19% and the average quarterly volume growth was 20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 76
Price Growth Rating: 53
SMR Rating: 87
Profit Risk Rating: 90
Seasonality Score: -20 (-100 ... +100)

Market Cap

The average market capitalization across the group is 103.39M. The market cap for tickers in the group ranges from 17.31M to 189.47M. MBOT holds the highest valuation in this group at 189.47M. The lowest valued company is SYBX at 17.31M.

High and low price notable news

The average weekly price growth across all stocks in the group was 19%. For the same group, the average monthly price growth was 22%, and the average quarterly price growth was 86%. MBOT experienced the highest price growth at 35%, while SYBX experienced the biggest fall at 3%.

Volume

The average weekly volume growth across all stocks in the group was 384%. For the same stocks of the group, the average monthly volume growth was 4,715% and the average quarterly volume growth was 1,292%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 72
P/E Growth Rating: 61
Price Growth Rating: 44
SMR Rating: 96
Profit Risk Rating: 100
Seasonality Score: -50 (-100 ... +100)
VS
MBOT vs. SYBX commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBOT is a Hold and SYBX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (MBOT: $4.16 vs. SYBX: $1.48)
Brand notoriety: MBOT and SYBX are both not notable
MBOT represents the Pharmaceuticals: Other, while SYBX is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: MBOT: 540% vs. SYBX: 57%
Market capitalization -- MBOT: $189.47M vs. SYBX: $17.31M
MBOT [@Pharmaceuticals: Other] is valued at $189.47M. SYBX’s [@Biotechnology] market capitalization is $17.31M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $167.92B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $99.72B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.07B. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBOT’s FA Score shows that 0 FA rating(s) are green whileSYBX’s FA Score has 1 green FA rating(s).

  • MBOT’s FA Score: 0 green, 5 red.
  • SYBX’s FA Score: 1 green, 4 red.
According to our system of comparison, both MBOT and SYBX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBOT’s TA Score shows that 6 TA indicator(s) are bullish while SYBX’s TA Score has 5 bullish TA indicator(s).

  • MBOT’s TA Score: 6 bullish, 4 bearish.
  • SYBX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both MBOT and SYBX are a good buy in the short-term.

Price Growth

MBOT (@Pharmaceuticals: Other) experienced а +35.06% price change this week, while SYBX (@Biotechnology) price change was +3.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.14%. For the same industry, the average monthly price growth was +1.84%, and the average quarterly price growth was +20.81%.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.49%. For the same industry, the average monthly price growth was +18.23%, and the average quarterly price growth was +32.72%.

Reported Earning Dates

MBOT is expected to report earnings on Nov 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+3.14% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Biotechnology (+4.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MBOT($189M) has a higher market cap than SYBX($17.3M). MBOT YTD gains are higher at: 271.429 vs. SYBX (5.714). SYBX has higher annual earnings (EBITDA): -11.07M vs. MBOT (-13.4M). MBOT has more cash in the bank: 32.7M vs. SYBX (17M). SYBX has less debt than MBOT: SYBX (0) vs MBOT (149K). MBOT (0) and SYBX (0) have equivalent revenues.
MBOTSYBXMBOT / SYBX
Capitalization189M17.3M1,092%
EBITDA-13.4M-11.07M121%
Gain YTD271.4295.7144,750%
P/E RatioN/A6.36-
Revenue00-
Total Cash32.7M17M192%
Total Debt149K0-
FUNDAMENTALS RATINGS
MBOT vs SYBX: Fundamental Ratings
MBOT
SYBX
OUTLOOK RATING
1..100
2777
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
3553
P/E GROWTH RATING
1..100
10023
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MBOT's Valuation (59) in the Biotechnology industry is in the same range as SYBX (86). This means that MBOT’s stock grew similarly to SYBX’s over the last 12 months.

MBOT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYBX (100). This means that MBOT’s stock grew similarly to SYBX’s over the last 12 months.

SYBX's SMR Rating (94) in the Biotechnology industry is in the same range as MBOT (98). This means that SYBX’s stock grew similarly to MBOT’s over the last 12 months.

MBOT's Price Growth Rating (35) in the Biotechnology industry is in the same range as SYBX (53). This means that MBOT’s stock grew similarly to SYBX’s over the last 12 months.

SYBX's P/E Growth Rating (23) in the Biotechnology industry is significantly better than the same rating for MBOT (100). This means that SYBX’s stock grew significantly faster than MBOT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBOTSYBX
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
MBOT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GIGM1.510.01
+0.67%
GigaMedia Limited
FF3.890.02
+0.52%
Future Fuel Corp
CNS76.540.27
+0.35%
Cohen & Steers
FNV182.60-2.50
-1.35%
Franco-Nevada Corp
NOAH12.24-0.31
-2.47%
Noah Holdings Limited

MBOT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with POAI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then POAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBOT
1D Price
Change %
MBOT100%
+8.05%
POAI - MBOT
37%
Loosely correlated
-1.23%
BNGO - MBOT
34%
Loosely correlated
+2.50%
CORBF - MBOT
33%
Loosely correlated
+3.23%
RCEL - MBOT
33%
Poorly correlated
-4.71%
OTCFF - MBOT
32%
Poorly correlated
-8.54%
More

SYBX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SYBX has been loosely correlated with NEUP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if SYBX jumps, then NEUP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYBX
1D Price
Change %
SYBX100%
+1.37%
NEUP - SYBX
64%
Loosely correlated
+2.23%
BTAI - SYBX
37%
Loosely correlated
+3.61%
SBHMY - SYBX
34%
Loosely correlated
N/A
MDGL - SYBX
31%
Poorly correlated
-0.59%
MEIP - SYBX
29%
Poorly correlated
+0.60%
More